Wade Thomas Iams, MD

Wade T. Iams, MD, discusses the impact of adagrasib on the treatment of patients with KRAS G12C-mutant NSCLC in the second line, as well as its integration into clinical practice.

Wade T. Iams, MD, discusses the impact of the phase 3 FLAURA2 trial in patients with EGFR-mutant non–small cell lung cancer, highlighting the notable improvements in progression-free survival that the approach elicits.

Martin Dietrich, MD, PhD, and Wade Thomas Iams, MD, review the value of TROP2 as a target in patients with NSCLC.

Experts review data on treatment with HER3-directed agents in NSCLC for patients with EGFR mutations.

Dr Wade Thomas Iams explains how trastuzumab deruxtecan became the standard-of-care for HER2-mutated non-small cell lung cancer.

Martin Dietrich, MD, PhD, details the molecular target CEACAM5 and its use in the treatment of patients with non-small cell lung cancer.

Drs Martin Dietrich and Wade Thomas Iams discuss the differences between the targets, payloads, and linker technologies of the antibody drug conjugates in development for lung cancer.

Wade Thomas Iams, MD, provides an overview of antibody drug conjugates in the treatment of patients with lung cancer, including challenges and impact on clinical practice.